Is white matter involved in patients entered into typical trials of neuroprotection?
about
White matter injury in ischemic stroke.Effect of Cyclosporine on Lesion Growth and Infarct Size within the White and Gray Matter.Neuronal NAMPT is released after cerebral ischemia and protects against white matter injuryTissue plasminogen activator prevents white matter damage following stroke.Demyelination as a rational therapeutic target for ischemic or traumatic brain injury.Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia.Neuroprotection and stroke: time for a compromise.The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.Aging of cerebral white matter.Axonal protection achieved by blockade of sodium/calcium exchange in a new model of ischemia in vivoEffects of Erythropoietin on Gliogenesis during Cerebral Ischemic/Reperfusion Recovery in Adult Mice.Toll-like Receptor 2: A Novel Therapeutic Target for Ischemic White Matter Injury and Oligodendrocyte Death.Soluble epoxide hydrolase inhibition Promotes White Matter Integrity and Long-Term Functional Recovery after chronic hypoperfusion in miceImplantation of Brain-Derived Extracellular Matrix Enhances Neurological Recovery after Traumatic Brain Injury.A Post-stroke Therapeutic Regimen with Omega-3 Polyunsaturated Fatty Acids that Promotes White Matter Integrity and Beneficial Microglial Responses after Cerebral Ischemia.Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy.C-Phycocyanin and Phycocyanobilin as Remyelination Therapies for Enhancing Recovery in Multiple Sclerosis and Ischemic Stroke: A Preclinical Perspective.Human In Vitro Models of Ischaemic Stroke: a Test Bed for TranslationNeuroprotection: where to now?
P2860
Q31080285-D822DB6D-F018-4D14-8D75-707422C2BAE4Q33606943-40F84749-EAEE-44AC-9ADE-CACB6C18001FQ34727045-AC0226C1-1952-4950-A4B5-71B0EC5BA231Q35213585-B4B5FB38-1B75-4442-B81D-5AF0BD76EB55Q36090107-DC4F40A6-3DB4-439E-AC78-FA721287A4B6Q36191138-ACB80796-8467-4ACC-BE67-7BD51926B94EQ36922560-2BE61BBB-386B-42F8-A560-B4BD9457455AQ38522653-FF9FB6AF-1C17-4107-AD3E-DCDE2D2487F2Q39014387-07A6D2B4-5473-4D3D-9D35-8F694B7A7A29Q40819221-5C110932-3D6B-45D2-B6EA-5802D4FA8FC3Q41108732-6A77A25F-AB6D-47E8-BB27-3BEBE384667CQ41128526-F948C9A1-3AC4-4867-9DCC-EA918834697FQ41354081-8462E657-5E27-4CB3-B449-125B9F9B7A10Q42184310-7EE354BB-049D-40C9-89E1-0A8F2FAC9C64Q48039676-82F2F2E3-5ABB-4855-A40B-2FF847C8DA3BQ48339775-6D09C644-CAD7-464E-A872-7D5B4A864E1AQ49272997-A509EC77-2067-4824-8008-8E2A71007971Q57563997-5F71E5C9-29A0-4ACD-B870-0FBE86B74505Q57564070-7CB1A297-49CC-4C26-A658-5E7B6EE79AF0
P2860
Is white matter involved in patients entered into typical trials of neuroprotection?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Is white matter involved in patients entered into typical trials of neuroprotection?
@en
Is white matter involved in patients entered into typical trials of neuroprotection?
@nl
type
label
Is white matter involved in patients entered into typical trials of neuroprotection?
@en
Is white matter involved in patients entered into typical trials of neuroprotection?
@nl
prefLabel
Is white matter involved in patients entered into typical trials of neuroprotection?
@en
Is white matter involved in patients entered into typical trials of neuroprotection?
@nl
P2093
P50
P1433
P1476
Is white matter involved in patients entered into typical trials of neuroprotection?
@en
P2093
Dennis Young
Indra Indra
Peter M Wright
Romesh Markus
Thanh G Phan
P304
P356
10.1161/01.STR.0000189748.52500.A7
P407
P577
2005-11-03T00:00:00Z